D-CSS_Att1_Purchase_Description_2024-12-17.pdf

PDF 137 KB Posted

Attached to
10x Genomics Chromium X Chromium Connect Trade
Solicitation number
75N95025Q00096
Issued by

About this file

This is a Purchase Description outlining NCATS' requirement for a new Chromium Connect platform from 10X Genomics for automating single-cell library construction workflows. The document details the need to replace the current platform which is no longer supported by the manufacturer. The required items include: 1 Chromium X & Accessory Kit with 12-month warranty, 1 Chromium GEM-X Single Cell 3' Kit v4 (16 rxns), 1 Chromium GEM-X Single Cell 3' Chip Kit v4 (4 chips), and 1 Dual Index Kit TT Set A (96 rxns). The government has a Chromium Connect instrument available for trade-in.

The equipment will support NCATS' Stem Cell Translation Laboratory's research into opioid addiction and pain through the HEAL Initiative, specifically focusing on developing human cell-based models and patient-derived iPSC lines. Delivery is required by December 31, 2024 to the NIH National Center for Advancing Translational Sciences facility in Rockville, MD. The acquisition is being conducted as a non-competitive purchase from 10x Genomics, as they are the sole manufacturer of the required equipment and compatible reagents needed for research continuity.

View the file

Other files

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

Version 11-30-2016-1 FAR Part 11—Describing Agency Needs

PURCHASE DESCRIPTION

1. Statement of Need and Purpose: NCATS requires a new Chromium Connect platform, as the current platform is no longer supported by the manufacturer. The Chromium Connect by 10X Genomics is a platform for automating single-cell library construction workflows, such as 3' RNA sequencing, ATAC sequencing, or DNA copy number variant analysis. These workflows offer insight into transcriptional and epigenetic landscapes on the single-cell level with unprecedented detail, however, they are extremely laborious. A single library preparation protocol for 1 to 8 samples for a 3' RNA sequencing application can take as many as 3 or more days for a skilled researcher. Automation of the protocols minimizes hands-on time and greatly increases sample throughput. Additionally, it leads to standardization of the procedures and virtually eliminates technical variation.

2. Background Information and Objective: Single-cell sequencing is a novel method that allows derivation of global transcriptomic profiles - information on the expression level and nature of the transcripts - from each cell analyzed. Previously, this was only possible from bulk populations of cells and thus only population-level averages were available. the term "global" refers to the fact that rather than picking a list of genes for targeted analysis, all the detectable transcripts are quantified. These innovations allow for unprecedented detail in studying how genes contribute to disease or how their expression correlates with cellular phenotypes and processes such as differentiation.

The opioid crisis highlights the urgent need for novel non-addictive pain medications, as well as improved treatments for opioid addiction and overdose. There is a need for pharmacological agents directed at novel targets to test new therapeutic hypotheses, new clinic-ready drugs directed at those targets, and new testing systems with the potential to be more predictive of human clinical response than traditionally used models. Through the Helping to End Addiction Long-term (HEAL) Initiative, NCATS will focus on the development of human cell-based models of opioid misuse and addiction and of pain. The Stem Cell Translation Laboratory (SCTL) is a state-of-the-art research facility within NCATS’ Division of Pre-Clinical Innovation is dedicated to addressing the scientific and technological challenges in the iPSC field. Specifically, the SCTL aims to develop a renewable supply of human cell-based models focusing on new patient-derived iPSC lines that give rise to specialized, functional nerve cells that are relevant for opioid misuse, addiction, and pain.

Single-cell sequencing methods have become widely used in every project that the SCTL has pursued to date. The SCTL has developed protocols for the derivation of multiple major novel cell types from human pluripotent stem cells (embryonic or induced pluripotent stem cells), such as nociceptor cells, multiple subtypes of neurons, astrocytes, glial cells, or trophectodermal/trophoblast cells. In the past year, organoid cultures have been added to the list of routinely used techniques. At the same time, the

Version 11-30-2016-1 FAR Part 11—Describing Agency Needs

SCTL is in the process of starting several collaborations with external expert research groups. These collaborations expand the in-vitro models by a number of novel cell types and methods. For all of these, single-cell sequencing applications are a cornerstone. For example, a method developed by the SCTL leads to differentiation of human pluripotent stem cells into nociceptors - pain-sensing peripheral neurons. Identifying the phenotype of the subpopulations of the cells is paramount for their application in research into nociception which directly advances the laboratory's contribution to addressing the opioid crisis.

3. Generic Name of Product:

Automated single cell analysis and partitioning instrument.

4. Purchase Description:

Chromium X & Accessory Kit,12 Mo. Warranty;

Chromium GEM-X Single Cell 3' Kit v4, 16 rxns;

Chromium GEM-X Single Cell 3' Chip Kit v4, 4 chips; and Dual Index Kit TT Set A 96 rxns

The Government has a Chromium Connect instrument available to trade-in.

5. Salient characteristics N/A

6. Quantity:

1x Chromium X & Accessory Kit,12 Mo. Warranty 1x Chromium GEM-X Single Cell 3' Kit v4, 16 rxns 1x Chromium GEM-X Single Cell 3' Chip Kit v4, 4 chips 1x Dual Index Kit TT Set A 96 rxns

7. Delivery Date: December 31, 2024.

Delivery address:

Attn: Seung Mi Ryu NIH - National Center for Advancing Translational Sciences Division of Preclinical Innovation Stem Cell Translation Laboratory 9800 Medical Center Dr.

Building B, Room 219 Rockville, MD 20850

8. Period of Performance: N/A

9. Option(s): N/A

File details come from the government source that posted it. Updated .